Fears over vaccines block

Share this article:
The weekly Cancer Letter says recent Capitol Hill testimony by the acting director of the National Cancer Institute (NCI) suggests that human papilloma virus (HPV) vaccines, objected to by the religious right, might have approval blocked by the FDA. Both Merck and GlaxoSmithKline are developing 
vaccines.

According to the Cancer Letter, NCI acting director John Niederhuber seemed to downplay the vaccines' importance for US women, notwithstanding one's success in an NCI-sponsored trial, when he appeared before the House Appropriations Subcommittee on Labor, HHS and Education.

However, in the third world, Niederhuber said, “the impact of this could be just absolutely huge.” The Cancer Letter says social conservatives are expected to oppose HPV vaccines at FDA the same way they opposed the emergency contraceptive Plan B.

The letter goes on to  quote Reproductive Health Technologies Project president Kirsten Moore as saying Niederhuber's testimony sounded “like the birth of a convenient excuse not to look at what HPV vaccines could do for this country.”

Some religious right advocates claim that HPV vaccines, like Plan B, would encourage sexual promiscuity, especially among the young.
Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.